Although C37 compound requires a chemical refinement in order to obtain a more active molecule, a clinical development of anti-uPAR drugs as a novel pharmacological therapy in human cancer carrying RAS activating mutations is warranted. The gene discussed is PLAUR; the disease is cancer.